Tuesday, January 4, 2011

Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016

Chronic Kidney Disease – Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData’s report on the pharmaceutical and healthcare industry – “Chronic Kidney Disease – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global chronic kidney disease market. This pharma report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
Scope
  • Annualized global chronic kidney disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
  • Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
  • Pipeline analysis data split across different phases by mechanism of action and emerging trends. Key classes of mechanism of action phosphate binders, erythropoietin (EPO) activators, nutrition supplements, iron replacement therapy, PTH synthesis inhibitor, Angiotensin Converting Enzyme (ACE) Inhibitor, endothelin antagonist, Angiotensin II Receptor Blocker, Antioxidant Inflammation Modulator, Direct renin inhibitor, IMPDH Inhibitor, Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor.
  • Analysis of the current and future competition in the global chronic kidney disease market. Key market players covered include Reata Pharmaceuticals, Keryx Pharmaceuticals, Cytochroma Inc, Affymax, Ineos Healthcare, Merck & Co Inc, Pfizer, Novartis AG, Amgen and Abbott Plc.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future chronic kidney disease market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global chronic kidney disease market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global chronic kidney disease market landscape? – Identify, understand and capitalize.
Buy Now: Market Research

Related Reports

at